DEBRIT 250MG TABLET

Introduction to DEBRIT 250MG TABLET

DEBRIT 250MG TABLET is a medication primarily used to treat certain types of lung cancer. It is specifically designed for patients with non-small cell lung cancer (NSCLC) that have specific gene mutations known as EGFR mutations. This tablet is often prescribed to patients who have not undergone prior chemotherapy.

Composition of DEBRIT 250MG TABLET

The active ingredient in DEBRIT 250MG TABLET is Gefitinib, which is an EGFR tyrosine kinase inhibitor. This means it works by blocking signals that promote cancer cell growth, specifically targeting mutated EGFR receptors.

Uses of DEBRIT 250MG TABLET

• Treatment of locally advanced non-small cell lung cancer (NSCLC)
• Treatment of metastatic NSCLC with EGFR mutations
• Prescribed for patients who have not received prior chemotherapy

Side effects of DEBRIT 250MG TABLET

Common side effects:

• Diarrhea
• Skin rash
• Nausea
• Vomiting
• Loss of appetite

Serious side effects:

• Liver toxicity
• Lung inflammation
• Severe diarrhea leading to dehydration

Precautions of DEBRIT 250MG TABLET

DEBRIT 250MG TABLET should not be taken by individuals without EGFR mutations, pregnant or breastfeeding women, or those with severe liver or kidney disease. It is also contraindicated for patients with a history of interstitial lung disease or those allergic to Gefitinib or any of its ingredients.

How to Take DEBRIT 250MG TABLET

• Take one tablet orally once daily.
• Consume at the same time each day for best results.
• Follow your doctor's instructions regarding dosage and duration.

Conclusion of DEBRIT 250MG TABLET

DEBRIT 250MG TABLET is a targeted therapy for certain types of lung cancer, offering hope to patients with specific genetic mutations. While it can be highly effective, it is important to be aware of potential side effects and take necessary precautions. Always consult with your healthcare provider for personalized advice and treatment plans.